Morgan Stanley Lowers Tempus AI (NASDAQ:TEM) Price Target to $70.00

Tempus AI (NASDAQ:TEM) had its target price decreased by investment analysts at Morgan Stanley from $85.00 to $70.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 36.48% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Piper Sandler reduced their price objective on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. BTIG Research lowered their target price on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. JPMorgan Chase & Co. reduced their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Mizuho assumed coverage on Tempus AI in a report on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.15.

Tempus AI Price Performance

TEM opened at $51.29 on Tuesday. Tempus AI has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a 50 day moving average of $60.57 and a two-hundred day moving average of $72.91. The company has a market cap of $9.13 billion, a P/E ratio of -36.38 and a beta of 5.29. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the completion of the sale, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. This trade represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the transaction, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 590,109 shares of company stock valued at $37,056,566 in the last three months. 26.27% of the stock is currently owned by company insiders.

Institutional Trading of Tempus AI

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Capital LLC boosted its stake in Tempus AI by 26.9% during the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after purchasing an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after buying an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI during the third quarter worth about $1,695,000. Vanguard Group Inc. raised its position in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Finally, Krane Funds Advisors LLC lifted its holdings in Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after acquiring an additional 19,358 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.